1-MT enhances potency of tumor cell lysate-pulsed dendritic cells against pancreatic adenocarcinoma by downregulating the percentage of tregs
- 17 June 2010
- journal article
- research article
- Published by Springer Nature in Current Medical Science
- Vol. 30 (3) , 344-348
Abstract
This study examined whether 1-methyl-tryptophan [1-MT, an indoleamine 2, 3-dioxygenase (IDO) inhibitor] could reduce CD4+CD25+ regulatory T cells (Tregs) proliferation and improve the anti-tumor efficacy of dendritic cells (DCs) pulsed with tumor cell lysate in the mice bearing pancreatic adenocarcinoma. The models of pancreatic adenocarcinoma were established in C57BL/6 mice by subcutaneous injection of Pan02 cells. Eight mice which were subcutaneously injected with PBS served as control. The expression of IDO was determined in tumor draining lymph nodes (TDLNs) and spleens of the murine pancreatic adenocarcinoma models. The prevalence of Tregs was measured in the TDLNs and spleens before and after 1-MT administration. The dendritic cells were pulsed with tumor cell lysate for preparing DC vaccine. The DC vaccine, as a single agent or in combination with 1-MT, was administered to pancreatic adenocarcinoma mice. The anti-tumor efficacy was determined after different treatments by regular observation of tumor size. The results showed that the levels of IDO mRNA and protein in tumor-bearing mice were significantly higher than those in the normal control mice. The percentage of Tregs in the spleen and TDLNs was also higer in tumor-bearing mice than in normal control mice (PP<0.01). Our results indicated that 1-MT may enhance anti-tumor efficacy of dendritic cells pulsed with tumor cell lysate by downregulating the percentage of Tregs.Keywords
This publication has 31 references indexed in Scilit:
- Tumor-derived TGF-β Mediates Conversion of CD4+Foxp3+ Regulatory T Cells in a Murine Model of Pancreas CancerJournal of Immunotherapy, 2009
- Enhanced immune stimulation by a therapeutic lymphoma tumor antigen vaccine produced in insect cells involves mannose receptor targeting to antigen presenting cellsVaccine, 2009
- Recent Advances in Cancer Vaccines: An OverviewJapanese Journal of Clinical Oncology, 2008
- CD4+FoxP3+ regulatory T cells confer infectious tolerance in a TGF-β–dependent mannerJournal of Experimental Medicine, 2008
- Steady state dendritic cells with forced IDO expression induce skin allograft tolerance by upregulation of regulatory T cellsTransplant Immunology, 2008
- The characterization and role of regulatory T cells in immune reactionsFrontiers in Bioscience-Landmark, 2008
- Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MTJournal of Cancer Research and Clinical Oncology, 2007
- Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenaseJournal of Clinical Investigation, 2007
- DC-based cancer vaccinesJournal of Clinical Investigation, 2007
- Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cellsJournal of Clinical Investigation, 2005